FDA announces new insulin recall due to potential labeling issue

Mylan Pharmaceuticals, a Viatris Company, is recalling one batch of its Insulin Glargine injections due to the risk of labels missing from some vials.

The batch, distributed from December 2021 to March 2022, included 10-mL vials of the company’s unbranded insulin glargine-yfgn, which is designed to control glycemic control in adult patients diagnosed with type 1 diabetes or type 2 diabetes. It can also be prescribed to pediatric patients diagnosed with type 1 diabetes.

“For patients receiving treatment with more than one type of insulin (e.g., both short and long-acting insulin), a missing label on Insulin Glargine vials could lead to a mix-up of products/strengths, which may result in less optimal glycemic control (either high or low blood sugar) which could result in serious complications,” according to an advisory on the U.S. Food and Drug Administration (FDA) website. “To date, no adverse events related to this recall have been received for this product.”

Retailers are asked to examine their inventory and discontinue the distribution of any included products. If consumers discover they have been sold an unlabeled product, they can return it.

“Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product,” according to the advisory.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."